Ligand id: 6941

Name: obinutuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: obinutuzumab

No information available.
Summary of Clinical Use
Initially approved to treat chronic lymphocytic leukemia (CLL) in combination with chemotherapy in patients who have received no prior therapy. In November 2012, this antibody was authorised as an orphan drug by the EMA for the treatment of CLL. Full EMA approval for CLL was granted in July 2014.
In February 2016, the US FDA expanded approval to include treatment of patients with follicular lymphoma (FL) who have relapsed after, or are refractory to, a rituximab-containing regimen. This new approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy.
Mechanism Of Action and Pharmacodynamic Effects
Obinutuzumab acts as an immunomodulator by targeting CD20 and killing B cells.
External links